Physician profile
Ashraf H Berry
NPI 1225083967
$3,161.56
in general payments reported to CMS, 2019-2025
31 companies · $877 in 2025
The $877 reported for 2025 was more than what 96% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $92.55 · 2021: $233 · 2022: $371 · 2023: $538 · 2024: $608 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $555.01 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $387.44 | 2019-2024 | Jornay Pm |
| Corium, LLC | $364.55 | 2022-2025 | Azstarys |
| Pfizer INC. | $212.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $211.41 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $206.98 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $165.08 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $146.97 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $105.44 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Alk-Abello, INC | $100.16 | 2023-2025 | Odactra, Grastek, Neffy |
| Neurelis, INC. | $94.73 | 2022-2024 | Valtoco |
| Tris Pharma INC | $90.56 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $67.43 | 2019-2025 | Relexxii |
| Adlon Therapeutics L.P. | $57.74 | 2019-2021 | |
| Shire North American Group INC | $40.37 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.06 | 2019-2021 | |
| Seqirus USA INC | $34.39 | 2022-2024 | Flucelvax |
| Kaleo, INC. | $33.11 | 2019-2020 | |
| Abbott Laboratories | $28.03 | 2025 | Id Now Instrument |
| Alexion Pharmaceuticals, INC. | $23.93 | 2024 | Strensiq |
| Sanofi-Aventis U.S. LLC | $23.59 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.55 | 2025 | |
| Sobi, INC | $22.79 | 2023 | |
| Verrica Pharmaceuticals INC. | $22.53 | 2024 | Ycanth |
| Phadia US INC. | $19.88 | 2025 | Immunocap |
| Genentech USA, INC. | $17.65 | 2021 | |
| Avion Pharmaceuticals | $16.93 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, Lp | $14.51 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.22 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.69 | 2023 | Flumist Quadrivalent |
| Aprecia Pharmaceuticals, LLC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.